Antibodies
28 August 2012
FDA Lifts Clinical Hold on Lpath’s iSONEP28 August 2012
Morphotek, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma27 August 2012
Genzyme Provides Update on U.S. LEMTRADA Filing24 August 2012
Eli Lilly and Company Announces Top-Line Results on Solanezumab Phase 3 Clinical Trials in Patients with Alzheimer’s Disease23 August 2012
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis22 August 2012
Symphogen Publishes Final Rozrolimupab (SYM001) Phase 2 Trial Results in ITP in BLOOD Journal15 August 2012
MORPHOTEK OPENS PILOT ANTIBODY MANUFACTURING PLANT11 August 2012
FDA Approves Lucentis (Ranibizumab Injection) for Treatment of Diabetic Macular Edema (DME)9 August 2012
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer8 August 2012
BTG Announces Data from Phase IIb Study of AZD97734 August 2012
U.S. FDA Approves ZALTRAP (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer30 July 2012
New Published Paper Shows Efficacy of Lpath’s Anti-LPA Antibody, Lpathomab, in Spinal Cord Injury ModelsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports